<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416871</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000468028</org_study_id>
    <secondary_id>LEONB-PERCY-DUO</secondary_id>
    <secondary_id>LEONB-ET99-057</secondary_id>
    <secondary_id>EU-20604</secondary_id>
    <secondary_id>ROCHE-LEONB-PERCY-DUO</secondary_id>
    <secondary_id>CHIRON-LEONB-PERCY-DUO</secondary_id>
    <nct_id>NCT00416871</nct_id>
  </id_info>
  <brief_title>Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>Cytokines in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Intravenous Interleukin and Subcutaneous Interferon-α Versus Subcutaneous Interleukin and Interferon-α for Good Prognosis Patients [PERCY DUO]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as interleukin-2 and interferon, may stimulate the&#xD;
      immune system in different ways and stop tumor cells from growing. It is not yet known&#xD;
      whether interleukin-2 given by infusion is more effective than interleukin-2 given by&#xD;
      injection when combined with interferon in treating metastatic kidney cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying interleukin-2 given by infusion to see&#xD;
      how well it works compared to interleukin-2 given by injection when combined with interferon&#xD;
      in treating patients with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the overall survival of patients with metastatic renal cell cancer treated with&#xD;
           intravenous vs subcutaneous interleukin-2 in combination with interferon alfa.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare progression-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare response rates (complete and partial) in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is an open-label, randomized, parallel-group, multicenter study. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive induction therapy comprising interleukin-2 (IL-2) IV&#xD;
           continuously over days 1-5, 15-19, 43-47, and 57-61 (weeks 1, 3, 7, and 9) and&#xD;
           interferon alfa (IFN-α) subcutaneously (SC) three times weekly in weeks 1-3 and 7-9.&#xD;
           Patients then undergo restaging. Patients achieving a complete response (CR), partial&#xD;
           response (PR), or stable disease (SD) then receive maintenance therapy comprising IL-2&#xD;
           IV continuously over 5 days and IFN-α SC three times weekly in weeks 1, 5, 9, and 13.&#xD;
&#xD;
        -  Arm II: Patients receive induction therapy comprising IL-2 SC twice daily on days 1-5,&#xD;
           8-12, 15-19, and 22-26 (weeks 1-4). Patients also receive IFN-α SC three times weekly in&#xD;
           weeks 1-4 and 6-9. Patients then undergo restaging. Patients achieving a CR, PR, or SD&#xD;
           then receive maintenance therapy comprising IL-2 SC as in induction therapy and IFN-α SC&#xD;
           three times weekly in weeks 1-4 and 8-11.&#xD;
&#xD;
      Quality of life is assessed at baseline, at the end of induction therapy, and then at the end&#xD;
      of maintenance therapy.&#xD;
&#xD;
      After completion of treatment, patients are followed every 3 months for 2 years and then&#xD;
      every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 220 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic renal cell adenocarcinoma&#xD;
&#xD;
               -  More than one resectable metastatic site&#xD;
&#xD;
               -  No unresectable lesions after local curative treatment (i.e., radiotherapy)&#xD;
&#xD;
               -  In case of secondary lesions suspected on imaging (&lt; 1 cm and/or sparse lesions),&#xD;
                  metastatic disease must be confirmed by biopsy OR disease progression documented&#xD;
                  by imaging performed over several weeks&#xD;
&#xD;
               -  If patient has known prior metastatic lesions, progressive disease must have been&#xD;
                  confirmed within the past 3 months by noninvasive techniques&#xD;
&#xD;
          -  Nephrectomized&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 90-100%&#xD;
&#xD;
          -  Hematocrit ≥ 30%&#xD;
&#xD;
          -  WBC ≥ 4,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 120,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine ≤ 1.7 mg/dL&#xD;
&#xD;
          -  FEV_1 ≥ 50%&#xD;
&#xD;
          -  No severe cardiac dysfunction (i.e., grade III/IV heart disease), including any of the&#xD;
             following:&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Coronary artery disease&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Severe arrhythmia&#xD;
&#xD;
          -  No active infections requiring antibiotic treatment&#xD;
&#xD;
          -  No severe neuropsychiatric condition&#xD;
&#xD;
          -  No geographical, psychological, or familial conditions that would preclude study&#xD;
             treatment&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  No severe autoimmune disease&#xD;
&#xD;
          -  No known chronic hepatitis&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No hepatitis B surface antigen positivity&#xD;
&#xD;
          -  No prior or concurrent other cancer, except basal cell skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  No severe pulmonary, hepatic, or renal condition that would preclude study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior wide-field radiotherapy&#xD;
&#xD;
          -  No prior allograft&#xD;
&#xD;
          -  No prior cytokines or chemotherapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Negrier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <results_reference>
    <citation>Négrier S, Perol D, Ravaud A, Bay JO, Oudard S, Chabaud S, Fargeot P, Delva R, Deplanque G, Gravis G, Escudier B; French Immunotherapy Group. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res. 2008 Sep 15;14(18):5907-12. doi: 10.1158/1078-0432.CCR-08-0236.</citation>
    <PMID>18794104</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

